Table 2 Effects of zafirlukast in asthmatic subjects maintained on β2-agonists alone
From: Tolerance and rebound with zafirlukast in patients with persistent asthma
β2-agonists alone + Placebo Change from baseline | β2-agonists alone + Zafirlukast Change from baseline | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Baseline (N = 7) | Weeks 0–5 (N = 6) | Weeks 6–10 (N = 5) | Week 11–12 (N = 5) | *W/D (N = 5) | Baseline (N = 14) | Weeks 0–5 (N = 13) | Weeks 6–10 (N = 12) | Week 11–12 (N = 12) | *W/D (N = 11) | |
Daily PEFR a.m., L/min | 375 (± 36.7) | -17.3 (± 8.6) | -12.2 (± 10.3) | +0.8 (± 7.5) | -1.2 (± 4.3) | 408 (± 30.9) | +14.9 (± 7.9) | +1.6 (± 8.5) | -3.2 (± 11.5) | -30.7 (± 10.9) |
Daily PEFR p.m., L/min | 374 (± 35.0) | +4.9 (± 6.6) | +14.2 (± 10.7) | +21.2 (± 11.7) | -9.4 (± 8.9) | 430 (± 27.4) | +4.2 (± 4.4) | -0.08 (± 5.7) | -5.8 (± 7.5) | -12.7 (± 8.2) |
FEV1, mL | 2.82 (± 0.33) | -170 (± 80) | +20.0 (± 10) | -258 (± 213) | +7.2 (± 128) | 2.90 (± 0.16) | +110 (± 60) | -12.5 (± 6.9) | +14.2 (± 72) | -214 (± 69.8) |
β2-agonist use per day | 4.6 (± 0.9) | -0.7 (± 0.3) | -1.3 (± 0.4) | -0.6 (± 0.5) | +0.2 (± 0.5) | 3.7 (± 0.5) | -0.7 (± 0.4) | -0.4 (± 0.5) | +0.2 (± 0.5) | +0.6 (± 0.3) |
Severity score | 1.9 (± 0.05) | -0.2 (± 0.1) | -0.3 (± 0.1) | -0.2 (± 0.2) | -0.04 (± 0.2) | 1.8 (± 0.08) | -0.2 (± 0.1) | -0.2 (± 0.1) | -0.2 (± 0.2) | +0.3 (± 0.2) |
**Total mornings | 4.1 (± 1.0) | -0.07 (± 0.5) | -0.2 (± 0.3) | -0.8 (± 0.4) | -0.2 (± 0.5) | 3.5 (± 0.7) | -1.1 (± 0.5) | -0.8 (± 0.6) | -0.3 (± 0.7) | +0.1 (± 0.5) |
**Total awakenings | 3.7 (± 1.3) | -1.1 (± 0.7) | -0.3 (± 1.7) | +0.7 (± 2.4) | -0.2 (± 0.7) | 1.4 (± 0.5) | -0.8 (± 0.4) | -0.9 (± 0.5) | +0.2 (± 0.7) | +0.9 (± 0.8) |